Mifepristone: What its new role in emergency contraception means
By Valerian Khakayi, September 25, 2026A medicine widely known for its role in medical abortion is now drawing attention for another potential use after the World Health Organization (WHO) recommended it as an additional emergency contraception option.
In new guidelines released on Wednesday, September 23, 2026, WHO expanded its recommendations on contraceptive options, including the use of mifepristone to be taken as soon as possible and within five days of unprotected intercourse.
The recommendation adds another option to existing emergency contraception methods and is intended to give people a wider range of choices when trying to prevent an unintended pregnancy.
According to the health organisation, the available evidence indicates that doses ranging from 10 mg to 50 mg are likely to be as safe and effective as other emergency contraceptive methods.
“WHO recommends mifepristone as an additional emergency contraception option, taken as soon as possible and within five days of unprotected intercourse. The evidence shows that mifepristone at doses of 10–50 mg is likely to be as safe and effective as other emergency contraceptive methods,” WHO stated.
Understanding mifepristone and its new role
Mifepristone is a medicine that blocks the action of progesterone, a hormone involved in maintaining pregnancy.
The drug is widely known for its use alongside misoprostol in medical abortion. However, WHO’s latest recommendation concerns a different use: low-dose mifepristone as emergency contraception after unprotected intercourse.
WHO’s new guideline identifies mifepristone for emergency contraception as one of three contraceptive methods not previously included in its guidance.
The distinction between its two uses is important. Emergency contraception is used after sex to prevent pregnancy, while medical abortion is used to end an established pregnancy.
Therefore, the new recommendation does not mean mifepristone is replacing existing emergency contraception methods or changing its established use in medical abortion. Instead, WHO is recognising its potential as an additional option for preventing pregnancy after unprotected sex.
WHO says expanding contraceptive options can give people greater choice based on factors such as convenience, accessibility, reliability and individual circumstances.
Additionally, WHO estimates that about 164 million women who want to delay or avoid pregnancy are not using contraception, highlighting the need for greater access to and choice of contraceptive methods.
Will mifepristone now be available everywhere?
Not necessarily.
WHO guidelines are designed to support countries as they consider which contraceptive methods and practices should be incorporated into their national programmes and clinical guidelines.
The new recommendation therefore does not automatically mean that mifepristone will immediately become available as emergency contraception in every country.
Availability, regulation and clinical practice can differ between countries, meaning people should check which emergency contraception options are authorised and available where they live.
What does the recommendation mean?
The latest guidance does not make mifepristone a replacement for existing emergency contraception. Instead, it adds another potential option for preventing pregnancy after unprotected sex.
WHO’s recommendation is based on evidence on the medicine’s effectiveness and safety at low doses, but its availability will depend on individual countries’ regulations and health programmes.
For anyone seeking emergency contraception, the appropriate option can depend on factors including timing, medical circumstances and what is authorised or available locally.
The broader message from WHO is that expanding the range of contraceptive methods can give people more options when deciding how to prevent an unintended pregnancy.
What other contraceptive changes did WHO announce?
The recommendation on mifepristone was part of a broader expansion of WHO’s contraceptive guidance.
The organisation also recommends that combined oral contraceptive pills can be used for extended periods of up to six months, or continuously for up to one year, rather than only following cyclical use.
Similarly, WHO also supports the use of contraceptive implants for up to five years, which could reduce the need for replacement procedures and clinic visits.
However, the organisation has called for more research on ormeloxifene before it is included in family planning programmes because of limited safety evidence.
WHO also recommended against adding quinestrol-containing contraceptive pills to national contraceptive programmes because of limited evidence and reports of serious adverse events.